

**THIS PRESS RELEASE IS NOT FOR GENERAL RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO, DIRECTLY OR INDIRECTLY, THE UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD VIOLATE APPLICABLE LAWS OR REGULATIONS**

*This is a joint press release by Koninklijke DSM N.V. (DSM), Firmenich International SA (Firmenich) and Danube AG, to be renamed DSM-Firmenich AG (the **Company** or **DSM-Firmenich**) in connection with the voluntary public exchange offer by the Company for all the issued and outstanding ordinary shares in the share capital of DSM (each such share, a **DSM Ordinary Share**) (the **Exchange Offer**). The Exchange Offer is not being made, and the DSM Ordinary Shares will not be accepted for purchase from or on behalf of any holder of DSM Ordinary Shares (a **DSM Shareholder**), in any jurisdiction in which the making of the Exchange Offer or acceptance thereof would not be in compliance with the securities or other laws or regulations of such jurisdiction or would require any registration, approval or filing with any regulatory authority not expressly contemplated by the terms of the offering circular in relation to the Exchange Offer dated 22 November 2022 (the **Offering Circular**).*



## **SUPPLEMENT TO THE OFFERING CIRCULAR DATED 22 NOVEMBER 2022 PUBLISHED**

**Kaiseraugst, Switzerland, Heerlen, the Netherlands and Geneva, Switzerland – 6 April 2023**

As indicated in our prior press releases of 31 March 2023 and 4 April 2023, DSM and Firmenich published today a supplement to the offering circular dated 22 November 2022. This supplement can be found on the transaction website: <https://www.creator-innovator.com/>.

For more information, please contact:

**DSM investor relations enquiries:**

Dave Huizing

Email: [investor.relations@dsm.com](mailto:investor.relations@dsm.com)

Telephone: +31 45 578 2864

**DSM media enquiries:**

FTI Consulting LLP

Edward Bridges / Alex Le May

Email: [scdsm@fticonsulting.com](mailto:scdsm@fticonsulting.com)

Telephone: +44 20 3727 1017

**Firmenich investor relations enquiries:**

Ingvild van Lysebetten

Email: [investor\\_relations@firmenich.com](mailto:investor_relations@firmenich.com)

Telephone: +41 79 833 7252

**Firmenich media enquiries:**

Brunswick Group

Joseph Chi Lo / Edward Brown

Email: [firmenich@brunswickgroup.com](mailto:firmenich@brunswickgroup.com)

Telephone: +44 20 7404 5959

**About Firmenich**

Firmenich, the world's largest privately-owned fragrance and taste company, was founded in Geneva, Switzerland, in 1895, and has been family-owned for 127 years. Firmenich is a business-to-business company specialized in the research, creation, manufacture and sale of perfumes, flavors, and ingredients. Renowned for its excellent research, as well as its leadership in sustainability, Firmenich offers its customers innovation in formulation, a broad palette of ingredients, and proprietary technologies such as biotechnology. Firmenich delivered CHF 4.7bn of sales in the financial year ended 30 June 2022.

**About DSM**

DSM has transformed during its 150+ year history into today's health, nutrition & bioscience global leader. The Dutch-Swiss company specializes in nutritional ingredients for food and feed with proven world-leading bioscience capabilities and an international network of high-quality manufacturing sites that underpin a business model of global products, local solutions and personalization and precision. For Health, Nutrition & Bioscience (excluding Materials), DSM delivered €7.3bn of sales in the calendar year 2021, with adjusted EBITDA of €1.4bn and an adjusted EBITDA margin of 19%.

**Transaction website**

Please visit [www.creator-innovator.com](http://www.creator-innovator.com) for additional materials on the Transactions.